Earnings Releases·Nov 12, 2026, 4:11 PM ET

Cibus — Third Quarter 2026 Earnings Summary

Revenue increased to $0.8 million for the quarter and $3.5 million for the nine-month period, while net loss narrowed to $21.9 million for the quarter and $65.3 million for the nine months compared to prior-year periods.
The Company anticipates an annualized net cash usage run rate of approximately $35 million for 2026, with existing cash of $10.7 million expected to fund operations into early 2027 despite an acute need for additional near-term funding.
Strategic focus remains on Rice and Sustainable Ingredients, with initial commercial launch for Rice traits targeted for 2028, biofragrance products approved for use, and a new partner-funded Mustar program in India initiated.
Significant cost reduction initiatives were implemented, including workforce reductions, consolidation of laboratory activities, and closure of the Oberlin and Roseville facilities, resulting in a 19% decrease in cash used in operating activities for the first nine months.
Regulatory progress includes EU legislation treating precise genomic edits as conventionally bred crops (excluding herbicide-tolerant and insecticidal plants) and UK approval for trial planting of Canola, though the Company faces risks regarding IP protection and capital access.